Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

[Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].

Classe JM, Muller M, Frenel JS, Berton Rigaud D, Ferron G, Jaffré I, Gladieff L.

J Gynecol Obstet Biol Reprod (Paris). 2010 May;39(3):183-90. doi: 10.1016/j.jgyn.2009.12.007. Epub 2010 Jan 29. Review. French.

2.

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.

de Bree E, Helm CW.

Expert Rev Anticancer Ther. 2012 Jul;12(7):895-911. doi: 10.1586/era.12.72. Review.

PMID:
22845405
3.

Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Robella M, Vaira M, Marsanic P, Mellano A, Borsano A, Cinquegrana A, Sottile A, De Simone M.

Minerva Chir. 2014 Feb;69(1):27-35.

PMID:
24675244
4.

Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.

Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F, Vanderbeeken D, Finet C, Cran S, Velu T.

Curr Pharm Des. 2012;18(25):3793-803. Review.

PMID:
22591422
5.

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.

Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.

Int J Gynecol Cancer. 2012 Jun;22(5):778-85. doi: 10.1097/IGC.0b013e31824d836c.

PMID:
22572845
6.

Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.

Massari R, Barone M, Basilico R, Carella C, Colasante A, De Tursi M, Filippone A, Guetti L, Mani A.

Minerva Chir. 2014 Feb;69(1):17-26.

PMID:
24675243
7.

Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Eskander RN, Cripe J, Bristow RE.

Curr Treat Options Oncol. 2014 Mar;15(1):27-40. doi: 10.1007/s11864-013-0264-2. Review.

PMID:
24338278
8.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
9.

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.

Cancer. 2008 Jul 15;113(2):315-25. doi: 10.1002/cncr.23553.

10.

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.

Chiva LM, Gonzalez-Martin A.

Gynecol Oncol. 2015 Jan;136(1):130-5. doi: 10.1016/j.ygyno.2014.11.072. Epub 2014 Nov 28.

PMID:
25434634
11.

Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.

Asero S, Caruso M, Vallone N, Luciani AG, Lombardo V, Terranova G, Ettore G, Giannone G.

In Vivo. 2009 Jul-Aug;23(4):645-7.

12.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D.

Gynecol Oncol. 2011 Aug;122(2):215-20. doi: 10.1016/j.ygyno.2011.05.004. Epub 2011 Jun 12.

PMID:
21665254
13.

[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].

Ferron G, Martinez A, Mery E, Querleu D, Thomas F, Chatelut E, Gladieff L.

Bull Cancer. 2009 Dec;96(12):1243-52. doi: 10.1684/bdc.2009.1005. Review. French.

14.

[Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].

Furet E, Chéreau E, Lambaudie E, Bannier M, Houvenaeghel G.

Gynecol Obstet Fertil. 2013 Sep;41(9):493-8. doi: 10.1016/j.gyobfe.2013.07.011. Epub 2013 Aug 21. French.

PMID:
23972918
15.

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V, Turco LC, Bottoni C, Scambia G.

Gynecol Oncol. 2014 Feb;132(2):303-6. doi: 10.1016/j.ygyno.2013.12.028. Epub 2013 Dec 27.

PMID:
24378877
16.

Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.

de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, Tsiftsis DD.

Cancer Treat Rev. 2006 Oct;32(6):471-82. Epub 2006 Aug 30. Review.

PMID:
16942841
17.

Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.

Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M.

Tumori. 2001 May-Jun;87(3):120-6.

PMID:
11504363
18.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
19.

Intraperitoneal hyperthermic chemotherapy in ovarian cancer.

Gori J, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, Felci N.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9.

PMID:
15823105
20.

[Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].

Chen YL, Liu YQ, Tang DH, Chu CN.

Zhonghua Fu Chan Ke Za Zhi. 2008 Feb;43(2):110-4. Chinese.

PMID:
18683749

Supplemental Content

Support Center